Treatment of hepatitis Delta
Heiner Wedemeyer, Svenja Hardtke, Michael P. Manns – 20 December 2013 – Watch a video presentation of this article
Hepatitis E: The endemic perspective
Rakesh Aggarwal – 20 December 2013 – Watch a video presentation of this article
Fate of abstracts presented at the 2004‐2008 International Liver Transplantation Society meetings
Patrick J. Hackett, Marina Guirguis, Nozomi Sakai, Tetsuro Sakai – 19 December 2013 – Only 20.5% to 61.6% of abstracts presented at biomedical meetings are subsequently published as full‐length articles. The aim of this study was to analyze the abstract‐to‐publication rate of International Liver Transplantation Society (ILTS) meeting abstracts. Abstracts presented at 5 consecutive annual ILTS meetings (2004‐2008) were included to ensure a minimum follow‐up period of 4 years.
Population health impact and cost‐effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China
Mehlika Toy, Joshua A. Salomon, Hao Jiang, Honglian Gui, Hui Wang, Jiangshe Wang, Jan Hendrik Richardus, Qing Xie – 19 December 2013 – Inactive chronic hepatitis B (CHB) carriers make up the largest group of hepatitis B virus‐infected patients, and China bears the largest total CHB burden of any country. We therefore assessed the population health impact and cost‐effectiveness of a strategy of lifelong monitoring for inactive CHB and treatment of eligible patients in Shanghai, China.
Speeding up hepatocyte proliferation: How triiodothyronine and β‐catenin join forces
- Read more about Speeding up hepatocyte proliferation: How triiodothyronine and β‐catenin join forces
Rolf Gebhardt – 19 December 2013
Raising‐flap technique for outflow reconstruction in living donor liver transplantation
Long‐Bin Jeng, Ashok Thorat, Ping‐Chun Li, Ming‐Li Li, Horng‐Ren Yang, Chun‐Chieh Yeh, Te‐Hung Chen, Chia‐Hao Hsu, Shih‐Chao Hsu, Kin‐Shing Poon – 18 December 2013
Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab‐containing chemotherapy
Shigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, Ryuzo Ueda – 17 December 2013
How does met regulate the survival/apoptosis balance?
Alessandro Furlan, David Tulasne – 17 December 2013
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation
Paul Martin, Andrea DiMartini, Sandy Feng, Robert Brown, Michael Fallon – 13 December 2013
Molecular mechanistic explanation for the spectrum of cholestatic disease caused by the S320F variant of ABCB4
Edward J. Andress, Michael Nicolaou, Marta R. Romero, Sandhia Naik, Peter H. Dixon, Catherine Williamson, Kenneth J. Linton – 12 December 2013 – ABCB4 flops phosphatidylcholine into the bile canaliculus to protect the biliary tree from the detergent activity of bile salts. Homozygous‐null ABCB4 mutations cause the childhood liver disease, progressive familial intrahepatic cholestasis, but cause and effect is less clear, with many missense mutations linked to less severe cholestatic diseases.